Part B: Patients must have either measurable disease or must be evaluable for MIBG response without evidence of Response Evaluation Criteria in Solid Tumors (RECIST) measurable lesions; patients with neuroblastoma in bone marrow only are not eligible
At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be allowed
At least one measurable disease site (as defined by Response Evaluation Criteria in Solid Tumors [RECIST]1.1) that has not been previously irradiated
Measurable or evaluable disease using Response Evaluation Criteria in Solid Tumors
Women with metastatic breast cancer, measurable or evaluable disease including bone metastasis only (as per the Response Evaluation Criteria in Solid Tumors [RECIST] v1.1)
Presence of measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1
Patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 =< 28 days prior to registration
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable or evaluable disease defined by Response Evaluation Criteria for Solid Tumors (RECIST) ver. 1.1
Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator
Measurable disease, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease per response evaluation criteria in solid tumors.
Presence of measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Presence of measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 is acceptable, except to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable disease by RECIST 1.1 is required
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
The patient must have radiographic measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in dose escalation; measurable disease by RECIST 1.1 is required in dose expansion
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.
Measurable disease is required per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
At least 1 site of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Subjects must have measurable disease (Response evaluation criteria in solid tumors (RECIST 1.1))
Measurable disease is required according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
PART I: Patients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
Subjects must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Subjects must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
Have advanced cancer (metastatic, recurrent or locally advanced) and measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)1.1
Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; stage IV or recurrent disease is required
Presence of at least one lesion with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria for response assessment
Measurable and evaluable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator
Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Participants must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Patients must have evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 limited to the abdomen and pelvis
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
Subjects must have measurable disease on physical exam or imaging per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
At least one measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1), local or distant
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable or evaluable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease (either primary site and/or nodal disease) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 criteria
Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Tumor burden must be radiographically measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Must have measurable disease (by Response Evaluation Criteria In Solid Tumors [RECIST] 1.1 for those with solid tumors; by Lugano classification for those with NHL), except those with AML, who must have histologically confirmed relapsed or refractory disease.
Disease must be measurable with at least 1 unidimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
At least 2 metastatic sites of which at least 1 must be measurable as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within 28 days prior to registration
Has measurable disease according to Response Criteria for Solid Tumors (RECIST v.1.1)
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for patients with solid malignancies
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have measurable disease by modified Response Evaluation Criteria in Solid Tumors (RECIST) or RECIST; examinations for assessment of measurable disease must have been completed within 28 days prior to registration
Subjects must have measurable disease on physical exam or imaging per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Have measurable or unmeasurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; however, note that patients in Cohort 1 that have undergone an R0 resection will be eligible for the trial
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable or evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Subjects with measurable disease, progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable or evaluable disease based on modified Response Evaluation Criteria in Solid Tumors (RECIST) for mesothelioma
Presence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients may have measurable disease only, non-measurable disease only, or both (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
Patient must have measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within 28 days prior to registration
Evaluable or measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, and meet the requirements for the intended study cohort
Presence of measurable recurrence, with Response Evaluation Criteria in Solid Tumors (RECIST) measurable disease at the time of intervention consent
Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; subjects with evaluable, but not measurable disease will be eligible for phase I
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients with advanced, measurable metastatic EGA, by Response Evaluation Criteria In Solid Tumors (RECIST) criteria
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
Patients must have measurable disease, defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
At least one measurable site of disease (as defined by Response Evaluation Criteria in Solid Tumors)
Presence of at least one site of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors 1.1
Patients must have at least one site of measurable disease (if applicable) (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 for solid tumors or the appropriate disease classification/criteria for the target population)
Measurable or evaluable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria
Patients may have either measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
At least one measurable site of disease (as defined by Response Evaluation Criteria in Solid Tumors), or other disease specific response assessment criteria, as appropriate (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or physical exam
A minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, bone only metastatic disease may be allowed on approval from study principal investigator (PI)
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Evaluable disease for dose escalation, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for dose expansions
At least two sites of disease that are measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Radiographically measurable disease present per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
At least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
At least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST).
Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable recurrence or metastases, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for mesothelioma
Presence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (not required for Part 1); presence of evaluable OR measurable disease for Part 1
Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
CA-125 only disease without Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable or otherwise evaluable disease
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease, i.e., at least one measurable lesion as per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria only for expansion cohorts
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Histologically confirmed, measurable or evaluable disease; patients should have at least one measurable lesion; if applicable, Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be used
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
All patients must have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have at least one site of measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria)
Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) or non-measurable disease, with measurement obtained within 4 weeks of registration
At least one site of measurable disease as determined by the Investigator, using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
The disease is evaluable by imaging per Response Evaluation Criteria in Solid Tumors 1.1.
Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Lugano Classification for subjects with DLBCL.
Have measurable or non-measurable, evaluable disease by the revised response evaluation criteria in solid tumors (RECIST) v.1.1
Measurable disease that is evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Patients must have disease that can be evaluated radiographically, this may be measurable disease or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 9.3 criteria
Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable or non-measurable disease (but radiologically evaluable) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
Patient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines
Evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
At least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST).
Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or bone-only disease
Patients must have measurable disease by modified Response Evaluation Criteria in Solid Tumors (RECIST) or RECIST; examinations for assessment of measurable disease must have been completed within 28 days prior to registration
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measureable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 or bone-only non measurable disease.
Measurable or evaluable disease will be included as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or bone-only disease
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST)
Patients must have disease (measurable or non-measurable acceptable) according to Response Evaluation Criteria In Solid Tumors (RECIST) v.1.1 criteria
Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Have the presence of measureable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Subjects with solid tumors, with the exception of castration-resistant prostate cancer (CRPC), must demonstrate measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measureable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteria
Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Part 2 only: Measureable tumor (Response Evaluation Criteria In Solid Tumors [RECIST] 1.1)
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumors
Measurable tumor (by Response Evaluation Criteria in Solid Tumors [RECIST] criteria)
Must have measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease by computed tomography (CT) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 to evaluate response
Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable or nonmeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Progressive NSCLC: Defined as increasing measurable disease, or the appearance of new measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria despite treatment.
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients with measurable or non-measurable metastatic disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable or non-measurable (but radiologically evaluable) disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria 1.1.
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Subjects must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in the previously irradiated field
Must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable disease by (Response Evaluation Criteria in Solid Tumors [RECIST 1.1]) or evaluable disease
Evidence of unidimensionally measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable disease according to Response Evaluation Criteria in Solid Tumors [RECIST 1.1];
Measurable or non-measurable (but evaluable) disease as defined via Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
EXPANSION COHORT ONLY: Participants must have measurable disease, defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Patients must have disease that can be evaluated radiographically; this may be measurable disease or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST).
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) outside of any prior radiation field.
Patients must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients may have no evidence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria or have measurable disease; CA-125 and other available markers will be obtained
Measurable disease as measured by response evaluation criteria in solid tumors (RECIST) criteria v 1.1.
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Evaluable or measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST).
Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
Patients must have measureable disease at screening by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria
Measurable disease based on modified Response Evaluation Criteria In Solid Tumors (RECIST)
Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable by Response Evaluation Criterion in Solid Tumors (RECIST) or evaluable disease.
Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) For multiple myeloma only:
Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1
Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1
Progression in measurable disease Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at the time of study entry
All patients enrolled will be required to have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria outside the radiation field
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Radiographically evaluable (measurable or non-measurable) disease (according to modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria
Presence of either evaluable disease or measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
The subject has measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Subjects must have measurable disease (Response evaluation criteria in solid tumors (RECIST 1.1)
Patients with measurable or non-measurable disease according to the response evaluation criteria in solid tumors (RECIST , v1.1)
Evaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) v.1.1
Patients with measurable or evaluable disease according to the response evaluation criteria in solid tumors
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Soft tissue disease progression as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Presence of at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
Disease that is measurable per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Histologically confirmed, measurable or evaluable disease; if disease is measurable Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be used
Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Have measurable disease based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1
Patients must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Phase Ib: Have evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at the time of study entry
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1, see Section 9)
Have measurable disease based on Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
Patients must have measureable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Has measureable disease by Response Evaluation Criteria In Solid Tumors (RECIST)
Has measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria at presentation
Have presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1